The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Cancer Epigenetics, Tumor Immunity, and Immunotherapy
Open accessAbstract
Epigenetic mechanisms, including DNA methylation, histone post-translational modifications, and chromatin structure regulation, are critical for the interactions between tumor and immune cells. Emerging evidence shows that tumors commonly hijack various epigenetic mechanisms to escape immune restriction. As a result, the pharmaceutical modulation of epigenetic regulators, including ‘writers’, ‘readers’, ‘erasers’, and ‘remodelers’, is able to normalize the impaired immunosurveillance and/or trigger antitumor immune responses. Thus, epigenetic targeting agents are attractive immunomodulatory drugs and will have major impacts on immuno-oncology. Here, we discuss epigenetic regulators of the cancer–immunity cycle and current advances in developing epigenetic therapies to boost anticancer immune responses, either alone or in combination with current immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A., Chen, Y.-T., & Old, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1669 · Cited by 1,582
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1×
“Key examples include translocation of KMT2A (MLL1) driving acute leukemia [51,52], and KMT6A (EZH2) gain-of-function mutations driving non-Hodgkin’s lymphoma [53].”
BackgroundAdvances in epigenetics link genetics to the environment and disease
Cavalli, G., & Heard, E. (2019) · Nature · doi:10.1038/s41586-019-1411-0 · Cited by 1,509
Kadoch, C., Hargreaves, D. C., Hodges, C., Elias, L., Ho, L., Ranish, J., & Crabtree, G. R. (2013) · Nature Genetics · doi:10.1038/ng.2628 · Cited by 1,458
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413 · cited 3×
“The estimated percentage of patients with cancer who are eligible for any of the approved ICBTs is still 50% in the USA [19].”
BackgroundEpigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348 · cited 1×
“After PD-1 blockade, reinvigorated effector T cells became re-exhausted, likely due to the failure of the blockade to reprogram the epigenetic landscape of exhausted T cells into effector T cells, shown by ATAC-seq analysis [70].”
BackgroundGenomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249
Moskophidis, D., Lechner, F., Pircher, H., & Zinkernagel, R. M. (1993) · Nature · doi:10.1038/362758a0 · Cited by 1,240
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
The epigenetic landscape of T cell exhaustion
Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933 · cited 2×
“ATAC-seq showed that a consistent chromatin-remodeling program dominated the exhaustion of effector T cells, which was absent in the formation of memory T cells [72].”
BackgroundDesign of amidobenzimidazole STING receptor agonists with systemic activity
Ramanjulu, J. M., Pesiridis, G. S., Yang, J., Concha, N., Singhaus, R., Zhang, S.-Y., Tran, J.-L., Moore, P., Lehmann, S., Eberl, H. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0705-y · Cited by 912
Bengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852
Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., et al. (2015) · Nature · doi:10.1038/nature15252 · Cited by 807
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Ghoneim, H. E., Fan, Y., Moustaki, A., Abdelsamed, H. A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G., Thomas, P. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.007 · Cited by 781
Chromatin state dynamics during blood formation
Lara-Astiaso, D., Weiner, A., Lorenzo-Vivas, E., Zaretsky, I., Jaitin, D. A., David, E., Keren-Shaul, H., Mildner, A., Winter, D., Jung, S., et al. (2014) · Science · doi:10.1126/science.1256271 · Cited by 776
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Sheng, W., LaFleur, M. W., Nguyen, T. H., Chen, S., Chakravarthy, A., Conway, J. R., Li, Y., Chen, H., Yang, H., Hsu, P.-H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.052 · Cited by 693 · cited 2×
“Interestingly, emerging evidence suggests that some epigenetics-targeting molecules, including drugs that are approved or under preclinical and clinical studies, modulate the tumor immune microenvironment and induce robust antitumor immune responses [24,25,27,31].”
BackgroundSuraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Fu, C., & Jiang, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03059 · Cited by 598
Xia, T., Konno, H., Ahn, J., & Barber, G. N. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.029 · Cited by 589
Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
Detection of Microbial Infections Through Innate Immune Sensing of Nucleic Acids
Tan, X., Sun, L., Chen, J., & Chen, Z. J. (2018) · Annual Review of Microbiology · doi:10.1146/annurev-micro-102215-095605 · Cited by 443
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J., Yokoyama, Y., Kossenkov, A. V., Bradner, J. E., Conejo-Garcia, J. R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.032 · Cited by 432
Li, H., Chiappinelli, K. B., Guzzetta, A. A., Easwaran, H., Yen, R.-W. C., Vatapalli, R., Topper, M. J., Luo, J., Connolly, R. M., Azad, N. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1782 · Cited by 430
T cell migration, search strategies and mechanisms
Krummel, M. F., Bartumeus, F., & Gérard, A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.16 · Cited by 423
Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity.
Cornacchia, E., Golbus, J., Maybaum, J., Strahler, J., Hanash, S., & Richardson, B. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.7.2197 · Cited by 420
Staron, M. M., Gray, S. M., Marshall, H. D., Parish, I. A., Chen, J. H., Perry, C. J., Cui, G., Li, M. O., & Kaech, S. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.013 · Cited by 385
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Dawson, M. A. (2017) · Science · doi:10.1126/science.aam7304 · Cited by 377
Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.02.006 · Cited by 352
Araki, Y., Wang, Z., Zang, C., Wood, W. H., Schones, D., Cui, K., Roh, T.-Y., Lhotsky, B., Wersto, R. P., Peng, W., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.006 · Cited by 328
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
Wang, D., Quiros, J., Mahuron, K., Pai, C.-C., Ranzani, V., Young, A., Silveria, S., Harwin, T., Abnousian, A., Pagani, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.050 · Cited by 318 · cited 10×
“In January 2020, tazemetostat, a KMT6A (EZH2) inhibitor, was approved for treatment of epithelioid sarcoma, making it the first approved histone ‘writer’ inhibitor and the first epidrug to treat solid tumors [79].”
InfluentialHogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.011 · Cited by 308
Procainamide Is a Specific Inhibitor of DNA Methyltransferase 1
Lee, B. H., Yegnasubramanian, S., Lin, X., & Nelson, W. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505593200 · Cited by 295
Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors
Magner, W. J., Kazim, A. L., Stewart, C., Romano, M. A., Catalano, G., Grande, C., Keiser, N., Santaniello, F., & Tomasi, T. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7017 · Cited by 294
Methyltransferase SETD2-Mediated Methylation of STAT1 Is Critical for Interferon Antiviral Activity
Chen, K., Liu, J., Liu, S., Xia, M., Zhang, X., Han, D., Jiang, Y., Wang, C., & Cao, X. (2017) · Cell · doi:10.1016/j.cell.2017.06.042 · Cited by 287
Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
Lu, C., Paschall, A. V., Shi, H., Savage, N., Waller, J. L., Sabbatini, M. E., Oberlies, N. H., Pearce, C., & Liu, K. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw283 · Cited by 266
Epigenetic landscapes reveal transcription factors that regulate CD8+ T cell differentiation
Yu, B., Zhang, K., Milner, J. J., Toma, C., Chen, R., Scott-Browne, J. P., Pereira, R. M., Crotty, S., Chang, J. T., Pipkin, M. E., et al. (2017) · Nature Immunology · doi:10.1038/ni.3706 · Cited by 254
Cause and Consequence of Cancer/Testis Antigen Activation in Cancer
Whitehurst, A. W. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140326 · Cited by 250
Siddle, H. V., Kreiss, A., Tovar, C., Yuen, C. K., Cheng, Y., Belov, K., Swift, K., Pearse, A.-M., Hamede, R., Jones, M. E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219920110 · Cited by 245
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy
Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., Xiong, L., Trojer, P., Aparicio, A., Subudhi, S. K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99760 · Cited by 244
Russ, B. E., Olshanksy, M., Smallwood, H. S., Li, J., Denton, A. E., Prier, J. E., Stock, A. T., Croom, H. A., Cullen, J. G., Nguyen, M. L. T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.11.001 · Cited by 221
Epigenetic mechanisms as a new approach in cancer treatment: An updated review
Fardi, M., Solali, S., & Farshdousti Hagh, M. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.06.003 · Cited by 209
Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function
Scharer, C. D., Barwick, B. G., Youngblood, B. A., Ahmed, R., & Boss, J. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301395 · Cited by 208
KDM5 histone demethylases repress immune response via suppression of STING
Wu, L., Cao, J., Cai, W. L., Lang, S. M., Horton, J. R., Jansen, D. J., Liu, Z. Z., Chen, J. F., Zhang, M., Mott, B. T., et al. (2018) · PLOS Biology · doi:10.1371/journal.pbio.2006134 · Cited by 172
Self-citationEssential role of HDAC6 in the regulation of PD‐L1 in melanoma
Lienlaf, M., Perez-Villarroel, P., Knox, T., Pabon, M., Sahakian, E., Powers, J., Woan, K. V., Lee, C., Cheng, F., Deng, S., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.012 · Cited by 170
Knox, T., Sahakian, E., Banik, D., Hadley, M., Palmer, E., Noonepalle, S., Kim, J., Powers, J., Gracia-Hernandez, M., Oliveira, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42237-3 · Cited by 170
DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge
Castillo-Aguilera, O., Depreux, P., Halby, L., Arimondo, P., & Goossens, L. (2017) · Biomolecules · doi:10.3390/biom7010003 · Cited by 164
Landscape of Tumor Antigens in T Cell Immunotherapy
Ilyas, S., & Yang, J. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501657 · Cited by 163
Ladle, B. H., Li, K.-P., Phillips, M. J., Pucsek, A. B., Haile, A., Powell, J. D., Jaffee, E. M., Hildeman, D. A., & Gamper, C. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524490113 · Cited by 152 · cited 2×
“Loss of DNMT3A leads to fewer effector cells, due to the ineffective repression of genes that are supposed to be silenced in effector cells [59].”
BackgroundNucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic
Agrawal, K., Das, V., Vyas, P., & Hajdúch, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.006 · Cited by 144
Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
Heiland, D. H., Haaker, G., Delev, D., Mercas, B., Masalha, W., Heynckes, S., Gaebelein, A., Pfeifer, D., Carro, M. S., Weyerbrock, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15031 · Cited by 130
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
Fukumoto, T., Fatkhutdinov, N., Zundell, J. A., Tcyganov, E. N., Nacarelli, T., Karakashev, S. V., Wu, S., Liu, Q., Gabrilovich, D. I., & Zhang, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1302 · Cited by 130
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O., Devenport, M., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0184-1 · Cited by 127
Knox, T. J., Sahakian, E., Banik, D., Hadley, M. M., Palmer, E., Noonepalle, S. K. R., Kim, J. S., Powers, J. J., Gracia-Hernandez, M., Oliveira, V. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51403-6 · Cited by 119
Adeegbe, D. O., Liu, S., Hattersley, M. M., Bowden, M., Zhou, C. W., Li, S., Vlahos, R., Grondine, M. R., Dolgalev, I., Ivanova, E. V., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0077 · Cited by 110
Mouse models of MLL leukemia: recapitulating the human disease
Milne, T. A. (2017) · Blood · doi:10.1182/blood-2016-10-691428 · Cited by 109
Tan, A. H. Y., Tu, W., McCuaig, R., Hardy, K., Donovan, T., Tsimbalyuk, S., Forwood, J. K., & Rao, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01351 · Cited by 104
He, B., Xing, S., Chen, C., Gao, P., Li, T., Shan, Q., Gullicksrud, J. A., Martin, M. D., Yu, S., Harty, J. T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.11.009 · Cited by 102
Berg, T., Thoene, S., Yap, D., Wee, T., Schoeler, N., Rosten, P., Lim, E. L., Bilenky, M., Mungall, A. J. J., Oellerich, T., et al. (2014) · Blood · doi:10.1182/blood-2012-12-473439 · Cited by 87
PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia
Goltz, D., Gevensleben, H., Grünen, S., Dietrich, J., Kristiansen, G., Landsberg, J., & Dietrich, D. (2016) · Leukemia · doi:10.1038/leu.2016.328 · Cited by 86
Ptaschinski, C., Mukherjee, S., Moore, M. L., Albert, M., Helin, K., Kunkel, S. L., & Lukacs, N. W. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004978 · Cited by 84
Gevensleben, H., Holmes, E. E., Goltz, D., Dietrich, J., Sailer, V., Ellinger, J., Dietrich, D., & Kristiansen, G. (2016) · Oncotarget · doi:10.18632/oncotarget.13161 · Cited by 84
Cook, P. C., Owen, H., Deaton, A. M., Borger, J. G., Brown, S. L., Clouaire, T., Jones, G., Jackson-Jones, L. H., Lundie, R. J., Marley, A. K., et al. (2015) · Nature Communications · doi:10.1038/ncomms7920 · Cited by 79
Nagai, Y., Ji, M. Q., Zhu, F., Xiao, Y., Tanaka, Y., Kambayashi, T., Fujimoto, S., Goldberg, M. M., Zhang, H., Li, B., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00174 · Cited by 78
Tomita, Y., Lee, M.-J., Lee, S., Tomita, S., Chumsri, S., Cruickshank, S., Ordentlich, P., & Trepel, J. B. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1219008 · Cited by 75
Chidamide in the treatment of peripheral T-cell lymphoma
Chan, T. S. Y., Tse, E., & Kwong, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s93528 · Cited by 75
Procaine is a specific DNA methylation inhibitor with anti‐tumor effect for human gastric cancer
Li, Y. Y., Wang, Y., Li, D., Zhang, Y., Zhao, T., & Chang-feng, L. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26407 · Cited by 73
Developmental Epigenetics: Phenotype and the Flexible Epigenome
John, R. M., & Rougeulle, C. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00130 · Cited by 68
Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors
Kortenhorst, M. S. Q., Wissing, M. D., Rodríguez, R., Kachhap, S. K., Jans, J. J. M., van der Groep, P., Verheul, H. M. W., Gupta, A. K., Aiyetan, P., van der Wall, E., et al. (2013) · Epigenetics · doi:10.4161/epi.25574 · Cited by 37
Epigenetic Flexibility Underlying Lineage Choices in the Adaptive Immune System
Kioussis, D., & Georgopoulos, K. (2007) · Science · doi:10.1126/science.1143777 · Cited by 24
Chromatin Architecture as an Essential Determinant of Dendritic Cell Function
Boukhaled, G. M., Corrado, M., Guak, H., & Krawczyk, C. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01119 · Cited by 24
Cited by
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 328
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
Zhang, S.-M., Cai, W. L., Liu, X., Thakral, D., Luo, J., Chan, L. H., McGeary, M. K., Song, E., Blenman, K. R. M., Micevic, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03994-2 · Cited by 272
Self-citationThe role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities
Cordani, M., Michetti, F., Zarrabi, A., Zarepour, A., Rumio, C., Strippoli, R., & Marcucci, F. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101076 · Cited by 40
Metadata
- Authors
- Cao, J., & Yan, Q.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 6
- Issue
- 7
- Pages
- 580-592
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W3015068997
- Cited by
- 346
- References
- 90
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.